- Home
- GNTA vs VNRX Comparison
GNTA vs VNRX Comparison
Compare GNTA & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GNTA | VNRX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | Italy | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 31.9M |
| IPO Year | N/A | 2012 |
Fundamental Metrics
Financial Performance| Metric | GNTA | VNRX |
|---|---|---|
| Price | $0.87 | $0.20 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 54.8K | ★ 1.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,233,511.00 |
| Revenue This Year | N/A | $68.22 |
| Revenue Next Year | N/A | $382.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 59.10 |
| 52 Week Low | $0.71 | $0.17 |
| 52 Week High | $10.00 | $0.94 |
Technical Indicators
Market Signals| Indicator | GNTA | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 40.78 | 39.09 |
| Support Level | $0.71 | $0.17 |
| Resistance Level | $1.70 | $0.27 |
| Average True Range (ATR) | 0.09 | 0.02 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 25.00 | 25.54 |
Price Performance
Historical ComparisonAbout GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About VNRX VolitionRX Limited
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.